Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?

Antiphospholipid Syndrome in Pregnancy Clinical Trial

Official title:
Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?

Status Withdrawn

Clinical Trial Summary

This study will address the value of adding intralipid infusion in reducing pregnancy complications related to antiphospholipid syndrome

Clinical Trial Description

This study will be conducted in the Department of Obstetrics and Gynecology, Tanta University on patients attending the antenatal care clinic and also on patients attending the researchers private clinics for antenatal care. The number of patients enrolled in the study will be 105 patients after application of inclusion and exclusion criteria. All women wil be thoroughly informed about the study aims and through discussion about the procedure, associated benefits and risks and will sign a written consent. ;

Study Design

Related Conditions & MeSH terms

Antiphospholipid Syndrome
Antiphospholipid Syndrome in Pregnancy
Pregnancy Complications
Syndrome

Clinical Trial Details

NCT number	NCT04274803
Study type	Interventional
Source	Tanta University
Contact
Status	Withdrawn
Phase	Phase 4
Start date	April 1, 2020
Completion date	May 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03100123` - AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study	Early Phase 1
Recruiting	`NCT03152058` - IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy	Phase 2
Recruiting	`NCT04275778` - HYDROxychloroquine in Syndrome Primary AntiPhospholipid	Phase 2
Recruiting	`NCT05378516` - Placental Pathology and Inflammatory Factor Analysis of OAPS
Recruiting	`NCT05679206` - Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pressure
Recruiting	`NCT03505840` - The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS